SULIS Trademark

Trademark Overview

On Friday, February 2, 2018, a trademark application was filed for SULIS with the United States Patent and Trademark Office. The USPTO has given the SULIS trademark a serial number of 87782227. The federal status of this trademark filing is REGISTERED as of Tuesday, June 11, 2019. This trademark is owned by E-Therapeutics Plc. The SULIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and pharmacological research services for early stage drug discovery; early stage drug discovery services, pharmaceutical product development; medical and scientific research, namely, analysis of disease networks, identifying drug targets, identifying proteins important in disease, identifying proteins to perturb for the treatment of disease, and identifying targets for a particular chemical compound; in-silico drug discovery; in silico-phenotypic screening, namely, for scientific and pharmaceutical research and drug discovery purposes; pre-clinical testing of drug discovery results for research purposes; drug designing services; medical and pharmacological research services for drug discovery involving the use of databases of biological and chemical interactions
sulis

General Information

Serial Number87782227
Word MarkSULIS
Filing DateFriday, February 2, 2018
Status700 - REGISTERED
Status DateTuesday, June 11, 2019
Registration Number5772664
Registration DateTuesday, June 11, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 26, 2019

Trademark Statements

Goods and ServicesMedical and pharmacological research services for early stage drug discovery; early stage drug discovery services, pharmaceutical product development; medical and scientific research, namely, analysis of disease networks, identifying drug targets, identifying proteins important in disease, identifying proteins to perturb for the treatment of disease, and identifying targets for a particular chemical compound; in-silico drug discovery; in silico-phenotypic screening, namely, for scientific and pharmaceutical research and drug discovery purposes; pre-clinical testing of drug discovery results for research purposes; drug designing services; medical and pharmacological research services for drug discovery involving the use of databases of biological and chemical interactions

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, February 12, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameE-Therapeutics Plc
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressOxfordshire OX298LN
GB
Party NameE-Therapeutics Plc
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressOxfordshire OX298LN
GB
Party NameE-Therapeutics Plc
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressOxfordshire OX298LN
GB

Trademark Events

Event DateEvent Description
Wednesday, May 23, 2018NON-FINAL ACTION WRITTEN
Tuesday, February 6, 2018NEW APPLICATION ENTERED
Monday, February 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 16, 2018ASSIGNED TO EXAMINER
Wednesday, May 23, 2018NON-FINAL ACTION WRITTEN
Wednesday, May 23, 2018NON-FINAL ACTION E-MAILED
Wednesday, May 23, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 27, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 26, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 26, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 15, 2018FINAL REFUSAL WRITTEN
Wednesday, August 15, 2018FINAL REFUSAL E-MAILED
Wednesday, August 15, 2018NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 6, 2019EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, February 6, 2019JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, February 6, 2019EX PARTE APPEAL-INSTITUTED
Wednesday, February 6, 2019TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, February 11, 2019ASSIGNED TO LIE
Tuesday, February 12, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 12, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 19, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 19, 2019EXPARTE APPEAL TERMINATED
Wednesday, March 6, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 26, 2019PUBLISHED FOR OPPOSITION
Tuesday, March 26, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 23, 2019TEAS DELETE 1(B) BASIS RECEIVED
Thursday, April 25, 2019WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
Tuesday, June 11, 2019REGISTERED-PRINCIPAL REGISTER
Thursday, October 13, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 13, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 13, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 11, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, October 13, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 13, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 13, 2022TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED

Related Keywords

sulis drug discovery research identifying services disease medical targets chemical purposes